
Julio C. Delgado, MD, MS
Executive Vice President
Chief of the Division of Clinical Pathology and Professor, University of Utah
Specialties
- Clinical pathology
- Immunology
- Histocompatibility
Education
- Master’s Degree—Epidemiology, Harvard School of Public Health
- Medical Degree—Universidad Industrial de Santander
- Resident—Pathology, Harvard Medical School
- Chief Resident—Pathology, Brigham and Women’s Hospital
- Fellowship—Immunogenetics, Dana-Farber Cancer Institute
- Postdoctoral Training—Immunology, CBR Institute for Biomedical Research
Certification/Affiliations
- American Board of Histocompatibility
- American Board of Pathology
Research Interests
- Immunogenecity to monoclonal antibody therapeutics
- Transplantation immunology
Recent Publications
- Pavlov IY, et al. Inductively coupled plasma mass spectrometry assay for quantification of free infliximab in serum. J Immunol Methods. 2019 Jul;470:33–9.
- Ravkov EV, et al. Evaluation of Mass Cytometry in the Clinical Laboratory. Cytometry B Clin Cytom. 2019 Jul;96(4):266–74.
- Lázár-Molnár E, Delgado JC. Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing. Clin Chem. 2019 Mar;65(3): 393–405.
- Genzen JR, et al. Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice. Arch Pathol Lab Med. 2018 Apr;142(4): 507–15.